Advances in dengue virus vaccines and therapeutic monoclonal antibodies

Yunchuan Ma

doi:10.54097/3qfp8j06

Authors

Yunchuan Ma

DOI:

https://doi.org/10.54097/3qfp8j06

Keywords:

Dengue virus; antibody-dependent enhancement; vaccine; monoclonal antibody.

Abstract

The prevalence of dengue fever (DF) in many countries has become a global burden. The pathogen, dengue virus (DENV) contains four serotypes, and oftentimes the antibody-dependent enhancement (ADE) due to the insufficient and imbalanced host immunity leads to severe dengue symptoms in heterologous secondary infections, posing a major difficulty ahead of modern medicine. Two technical routes, vaccine and monoclonal antibody (mAb) have been widely explored and testified at various levels. Tetravalent vaccines, especially chimeric live-attenuated viruses (LAV), have been proven to induce a relatively well-rounded immune response, while other categories including virus-like particle (VLP) are also of high potential. Therapeutic mAbs also have been shown to target epitopes that can be cross-neutralizing, covering not only individual structural and non-structural proteins but also quaternary conformation of virion surface. Undoubtedly limitations of previous research have directed the refinement of vector design, efficacy assessment, and other processes, although several challenges still exist today.

Downloads

Download data is not yet available.

References

World Health Organization, Dengue and severe dengue fact sheet. March 17, 2023. Retrieved on: August 11, 2023. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

Wilder-Smith, Annelies et al. “Dengue.” Lancet (London, England) vol. 393, 10169 (2019): 350-363.

World Health Organization, Dengue - the Region of the Americas. July 19, 2023. Retrieved on: August 11, 2023. Retrieved from: https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON475

Wu, Tiantian et al. “Dengue fever and dengue virus in the People's Republic of China.” Reviews in medical virology vol. 32, 1 (2022): e2245.

Sarker, Animesh et al. “Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.” Frontiers in immunology vol. 14 1200195. 2 Jun. 2023.

Eckels, K H et al. “Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development.” Infection and immunity vol. 14, 5 (1976): 1221-7.

Dittmar, D et al. “Monoclonal antibodies specific for dengue virus type 3.” Journal of clinical microbiology vol. 12, 1 (1980): 74-8.

Khetarpal, Niyati, and Ira Khanna. “Dengue Fever: Causes, Complications, and Vaccine Strategies.” Journal of immunology research vol. 2016 (2016): 6803098.

Guzman, Maria G, and Eva Harris. “Dengue.” Lancet (London, England) vol. 385, 9966 (2015): 453-65.

Kuhn, Richard J et al. “Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.” Cell vol. 108, 5 (2002): 717-25.

Zonetti, Luiz F C et al. “Molecular Aspects of the Dengue Virus Infection Process: A Review.” Protein and peptide letters vol. 25, 8 (2018): 712-719.

Pintado Silva, Jessica, and Ana Fernandez-Sesma. “Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.” The Journal of general virology vol. 104, 3 (2023): 001831.

Ooi, Eng Eong, and Shirin Kalimuddin. “Insights into dengue immunity from vaccine trials.” Science translational medicine vol. 15,704 (2023): eadh3067.

Dai, Yu-Ching et al. “Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines.” Frontiers in immunology vol. 14 1202055. 24 Jul. 2023.

Patel, Sanjay S et al. “Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 76, 3 (2023): e1350-e1359.

Russell, Kevin L et al. “A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.” Human vaccines & immunotherapeutics vol. 18, 5 (2022): 2046960.

Kallas, Esper G et al. “Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.” The Lancet. Infectious diseases vol. 20, 7 (2020): 839-850.

Collett, Simon et al. “Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates.” Frontiers in microbiology vol. 14 1065609. 7 Jun. 2023.

Veena Rani, N et al. “Efficient generation and characterization of chimeric dengue viral-like particles.” Biochemical and biophysical research communications vol. 654 (2023): 10-17.

A Dowd, Kimberly et al. “prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis.” Proceedings of the National Academy of Sciences of the United States of America vol. 120, 3 (2023): e2218899120.

Tan, Brandon E K et al. “Identification of Key Residues in Dengue Virus NS1 Protein That Are Essential for Its Secretion.” Viruses vol. 15, 5 1102. 30 Apr. 2023.

Sootichote, Rochanawan et al. “Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and Zika Virus Infections.” Biomedicines vol. 11, 1 227. 16 Jan. 2023.

Tien, Sen-Mao et al. “Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse model.” PLoS pathogens vol. 18, 4 e1010469. 29 Apr. 2022.

França, Renato Kaylan Alves de Oliveira et al. “New Anti-Flavivirus Fusion Loop Human Antibodies with Zika Virus-Neutralizing Potential.” International journal of molecular sciences vol. 23, 14 7805. 15 Jul. 2022.

Sarker, Animesh et al. “Structure-guided affinity maturation of a single-chain variable fragment antibody against the Fu-bc epitope of the dengue virus envelope protein.” The Journal of biological chemistry vol. 298, 4 (2022): 101772.

Sharma, Arvind et al. “The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses.” Cell vol. 184, 25 (2021): 6052-6066.e18.

Young, Ellen et al. “Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.” Cell host & microbe vol. 27, 5 (2020): 710-724.e7.

Dejnirattisai, Wanwisa et al. “Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.” Nature immunology vol. 17, 9 (2016): 1102-8.

Goethals, Olivia et al. “Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.” Nature vol. 615, 7953 (2023): 678-686.